Abstract

Metastasis is the most life-threatening complication in all cancers. The chemokine receptor 4 (CXCR4) is expressed at high levels in many breast-cancer tumors and may modulate metastasis. We compared the time-tometastasis and the sites of metastasis between breast-cancer tumors expressing CXCR4 at high or low levels.We enrolled 191 early breast cancer patients in our study. The expression of CXCR4 was evaluated using immunohistochemical staining, and the patients were divided into low-level (CXCR4-) and high-level (CXCR4+) CXCR4 expression groups. Associations between the patients' level of CXCR4 expression and their basic clinical characteristics, time-to-metastasis, and metastatic sites were examined using a Cox proportional-hazards regression model. A total of 107 CXCR4+ patients (56%) were identified. No statistical differenceswere evident in basic characteristics between the CXCR4+ and CXCR4- groups. The CXCR4+ group had a higher incidence of distant metastasis during the first year (10.3% versus 1.1%, P=0.009) and shorter event-free survival (17.43 months versus 27.5 months, P=0.026) than those of the CXCR4- group. The CXCR4+ group also had a higher incidence of bone metastasis (P=0.008) than the CXCR4- group. No significant difference in metastasis sites in other organs was observed between the two groups. A high level of CXCR4 expression in breast cancer is associated with early distant and bone metastases. The CXCR4+ phenotype may be a useful predictor for the prevention of early treatment failure and bone metastasis in breast cancer patients. This retrospective study shows that a high expression of CXCR4 in breast cancer is associated with earlier distant metastasis and bone metastasis in breast cancer.

Original languageEnglish
Pages (from-to)1581-1588
Number of pages8
JournalTumor Biology
Volume35
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Chemokine Receptors
Incidence
Treatment Failure
Proportional Hazards Models
Disease-Free Survival
Retrospective Studies
Staining and Labeling
Phenotype
Neoplasms

Keywords

  • Bone metastasis
  • Breast neoplasm
  • CXCR4
  • Metastasis

ASJC Scopus subject areas

  • Cancer Research

Cite this

High-level expression of CXCR4 in breast cancer is associated with early distant and bone metastases. / Hung, Chin-Sheng; Su, Hou Yu; Liang, Hung-Hua; Lai, Chieh Wen; Chang, Yo-Cheng; Ho, Yuan-Soon; Wu, Chih-Hsiung; Ho, Jau-Der; Wei, Po-Li; Chang, Yu-Jia.

In: Tumor Biology, Vol. 35, No. 2, 2014, p. 1581-1588.

Research output: Contribution to journalArticle

Hung, Chin-Sheng ; Su, Hou Yu ; Liang, Hung-Hua ; Lai, Chieh Wen ; Chang, Yo-Cheng ; Ho, Yuan-Soon ; Wu, Chih-Hsiung ; Ho, Jau-Der ; Wei, Po-Li ; Chang, Yu-Jia. / High-level expression of CXCR4 in breast cancer is associated with early distant and bone metastases. In: Tumor Biology. 2014 ; Vol. 35, No. 2. pp. 1581-1588.
@article{93ea2d39d3974ad19164018baa3bd1fc,
title = "High-level expression of CXCR4 in breast cancer is associated with early distant and bone metastases",
abstract = "Metastasis is the most life-threatening complication in all cancers. The chemokine receptor 4 (CXCR4) is expressed at high levels in many breast-cancer tumors and may modulate metastasis. We compared the time-tometastasis and the sites of metastasis between breast-cancer tumors expressing CXCR4 at high or low levels.We enrolled 191 early breast cancer patients in our study. The expression of CXCR4 was evaluated using immunohistochemical staining, and the patients were divided into low-level (CXCR4-) and high-level (CXCR4+) CXCR4 expression groups. Associations between the patients' level of CXCR4 expression and their basic clinical characteristics, time-to-metastasis, and metastatic sites were examined using a Cox proportional-hazards regression model. A total of 107 CXCR4+ patients (56{\%}) were identified. No statistical differenceswere evident in basic characteristics between the CXCR4+ and CXCR4- groups. The CXCR4+ group had a higher incidence of distant metastasis during the first year (10.3{\%} versus 1.1{\%}, P=0.009) and shorter event-free survival (17.43 months versus 27.5 months, P=0.026) than those of the CXCR4- group. The CXCR4+ group also had a higher incidence of bone metastasis (P=0.008) than the CXCR4- group. No significant difference in metastasis sites in other organs was observed between the two groups. A high level of CXCR4 expression in breast cancer is associated with early distant and bone metastases. The CXCR4+ phenotype may be a useful predictor for the prevention of early treatment failure and bone metastasis in breast cancer patients. This retrospective study shows that a high expression of CXCR4 in breast cancer is associated with earlier distant metastasis and bone metastasis in breast cancer.",
keywords = "Bone metastasis, Breast neoplasm, CXCR4, Metastasis",
author = "Chin-Sheng Hung and Su, {Hou Yu} and Hung-Hua Liang and Lai, {Chieh Wen} and Yo-Cheng Chang and Yuan-Soon Ho and Chih-Hsiung Wu and Jau-Der Ho and Po-Li Wei and Yu-Jia Chang",
year = "2014",
doi = "10.1007/s13277-013-1218-9",
language = "English",
volume = "35",
pages = "1581--1588",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - High-level expression of CXCR4 in breast cancer is associated with early distant and bone metastases

AU - Hung, Chin-Sheng

AU - Su, Hou Yu

AU - Liang, Hung-Hua

AU - Lai, Chieh Wen

AU - Chang, Yo-Cheng

AU - Ho, Yuan-Soon

AU - Wu, Chih-Hsiung

AU - Ho, Jau-Der

AU - Wei, Po-Li

AU - Chang, Yu-Jia

PY - 2014

Y1 - 2014

N2 - Metastasis is the most life-threatening complication in all cancers. The chemokine receptor 4 (CXCR4) is expressed at high levels in many breast-cancer tumors and may modulate metastasis. We compared the time-tometastasis and the sites of metastasis between breast-cancer tumors expressing CXCR4 at high or low levels.We enrolled 191 early breast cancer patients in our study. The expression of CXCR4 was evaluated using immunohistochemical staining, and the patients were divided into low-level (CXCR4-) and high-level (CXCR4+) CXCR4 expression groups. Associations between the patients' level of CXCR4 expression and their basic clinical characteristics, time-to-metastasis, and metastatic sites were examined using a Cox proportional-hazards regression model. A total of 107 CXCR4+ patients (56%) were identified. No statistical differenceswere evident in basic characteristics between the CXCR4+ and CXCR4- groups. The CXCR4+ group had a higher incidence of distant metastasis during the first year (10.3% versus 1.1%, P=0.009) and shorter event-free survival (17.43 months versus 27.5 months, P=0.026) than those of the CXCR4- group. The CXCR4+ group also had a higher incidence of bone metastasis (P=0.008) than the CXCR4- group. No significant difference in metastasis sites in other organs was observed between the two groups. A high level of CXCR4 expression in breast cancer is associated with early distant and bone metastases. The CXCR4+ phenotype may be a useful predictor for the prevention of early treatment failure and bone metastasis in breast cancer patients. This retrospective study shows that a high expression of CXCR4 in breast cancer is associated with earlier distant metastasis and bone metastasis in breast cancer.

AB - Metastasis is the most life-threatening complication in all cancers. The chemokine receptor 4 (CXCR4) is expressed at high levels in many breast-cancer tumors and may modulate metastasis. We compared the time-tometastasis and the sites of metastasis between breast-cancer tumors expressing CXCR4 at high or low levels.We enrolled 191 early breast cancer patients in our study. The expression of CXCR4 was evaluated using immunohistochemical staining, and the patients were divided into low-level (CXCR4-) and high-level (CXCR4+) CXCR4 expression groups. Associations between the patients' level of CXCR4 expression and their basic clinical characteristics, time-to-metastasis, and metastatic sites were examined using a Cox proportional-hazards regression model. A total of 107 CXCR4+ patients (56%) were identified. No statistical differenceswere evident in basic characteristics between the CXCR4+ and CXCR4- groups. The CXCR4+ group had a higher incidence of distant metastasis during the first year (10.3% versus 1.1%, P=0.009) and shorter event-free survival (17.43 months versus 27.5 months, P=0.026) than those of the CXCR4- group. The CXCR4+ group also had a higher incidence of bone metastasis (P=0.008) than the CXCR4- group. No significant difference in metastasis sites in other organs was observed between the two groups. A high level of CXCR4 expression in breast cancer is associated with early distant and bone metastases. The CXCR4+ phenotype may be a useful predictor for the prevention of early treatment failure and bone metastasis in breast cancer patients. This retrospective study shows that a high expression of CXCR4 in breast cancer is associated with earlier distant metastasis and bone metastasis in breast cancer.

KW - Bone metastasis

KW - Breast neoplasm

KW - CXCR4

KW - Metastasis

UR - http://www.scopus.com/inward/record.url?scp=84898865424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898865424&partnerID=8YFLogxK

U2 - 10.1007/s13277-013-1218-9

DO - 10.1007/s13277-013-1218-9

M3 - Article

C2 - 24101191

AN - SCOPUS:84898865424

VL - 35

SP - 1581

EP - 1588

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 2

ER -